Des Produits Nestle S.A. So... Net Worth

The estimated Net Worth of Des Produits Nestle S.A. So... is at least $665 Milion dollars as of 13 October 2020. Des So owns over 54,117,287 units of Aimmune Therapeutics Inc stock worth over $664,810,403 and over the last 4 years Des sold AIMT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Des So AIMT stock SEC Form 4 insiders trading

Des has made over 1 trades of the Aimmune Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Des bought 54,117,287 units of AIMT stock worth $1,867,046,402 on 13 October 2020.

The largest trade Des's ever made was buying 54,117,287 units of Aimmune Therapeutics Inc stock on 13 October 2020 worth over $1,867,046,402. On average, Des trades about 54,117,287 units every 0 days since 2020. As of 13 October 2020 Des still owns at least 23,408,817 units of Aimmune Therapeutics Inc stock.

You can see the complete history of Des So stock trades at the bottom of the page.

What's Des So's mailing address?

Des's mailing address filed with the SEC is AVENUE NESTLE 55, , CH-1800, VEVEY, V8, .

Insiders trading at Aimmune Therapeutics Inc

Over the last 9 years, insiders at Aimmune Therapeutics Inc have traded over $19,285,948 worth of Aimmune Therapeutics Inc stock and bought 61,698,079 units worth $2,225,231,200 . The most active insiders traders include Des Produits Nestle S.A. So..., Patrick G Enright oraz Des Produits Nestle S.A.Nes.... On average, Aimmune Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $21,038,606. The most recent stock trade was executed by Des Produits Nestle S.A. So... on 13 October 2020, trading 54,117,287 units of AIMT stock currently worth $1,867,046,402.

What does Aimmune Therapeutics Inc do?

Complete history of Des So stock trades at Aimmune Therapeutics Inc

Aimmune Therapeutics Inc executives and stock owners

Aimmune Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stacey Denenberg Seltzer,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Susan E. Barrowcliffe,
  General Manager, Europe
• Capital Partners Ii, Llc Ta...,
  
• Kathryn E Falberg,
  Director
• Daniel C Md Adelman,
  Chief Medical Officer
• Mary M. Rozenman,
  See Remarks
• Capital Management Ii, Llc ...,
  
• Capital Partners Ii, Llc Lo...,
  
• Gregory Behar,
  Director
• Douglas T. Sheehy,
  See Remarks
• Mark T Iwicki,
  Director
• Eric Bjerkholt,
  Chief Financial Officer
• Mark Mcdade,
  Director
• Warren L. De Souza,
  Chief Financial Officer
• Robert Myles Elfont,
  Chief Medical Officer
• Jayson Donald Alexander Dallas,
  President and CEO
• Health Science Us Holdings,...,
  
• Des Produits Nestle S.A.Nes...,
  
• Bakker Juliet Tammenoms,
  10% owner
• Stephen George Dilly,
  See Remarks
• Andrew Oxtoby,
  Chief Commercial Officer
• Capital Partners Ii, Llc Ta...,
  
• Patrick G Enright,
  Director
• Brett K Haumann,
  Director
• Des Produits Nestle S.A. So...,
  10% owner